Anti-inflammatory effect of a new piperazine derivative: (4-methylpiperazin-1-yl)(1-phenyl-1H-pyrazol-4-yl)methanone

Página do item simplificado
dc.creatorBatista, Daniel da Costa
dc.creatorSilva, Daiany Priscilla Bueno da
dc.creatorFlorentino, Iziara Ferreira
dc.creatorCardoso, Carina Sofia
dc.creatorGonçalves, Merita Pereira
dc.creatorValadares, Marize Campos
dc.creatorLiao, Luciano Morais
dc.creatorSanz Lobón, Germán
dc.creatorVaz, Boniek Gontijo
dc.creatorCosta, Elson Alves
dc.creatorMenegatti, Ricardo
dc.date.accessioned2023-08-03T15:09:20Z
dc.date.available2023-08-03T15:09:20Z
dc.date.issued2017
dc.description.abstractAims This study investigates the anti-nociceptive and anti-inflammatory effects of new piperazine compound (LQFM182) as well as the toxicity acute in vitro. Main methods To evaluate the anti-nociceptive activity, the acetic acid-induced abdominal writhing test, tail flick test and formalin-induced pain test were used. The anti-inflammatory activity was evaluated using the models of paw oedema and pleurisy induced by carrageenan and some inflammatory parameters were evaluated, including cell migration, myeloperoxidase enzyme activity and the levels of TNF-α and IL-1β cytokines in pleural exudate. The acute oral systemic toxicity of LQFM182 in mice was evaluated through the neutral red uptake (nru) assay. Key findings LQFM182 (50, 100 or 200 mg/kg, p.o.) decreased the number of writhings induced by acetic acid in a dose-dependent manner, and an intermediate dose (100 mg/kg, p.o.) reduced the paw licking time of animals in the second phase of the formalin test. Furthermore, LQFM182 (100 mg/kg, p.o.) reduced oedema formation at all hours of the paw oedema induced by carrageenan test and in pleurisy test reduced cell migration from the reduction of polymorphonuclear cells, myeloperoxidase enzyme activity and the levels of pro-inflammatory cytokines IL-1β and TNF-α. Therefore, it was classified in GHS category 300 < LD50 < 2000 mg/kg.pt_BR
dc.identifier.citationBATISTA, Daniel C. et al. Anti-inflammatory effect of a new piperazine derivative: (4-methylpiperazin-1-yl)(1-phenyl-1H-pyrazol-4-yl)methanone. Inflammopharmacology, London, v. 26, p. 217-226, 2018. DOI: 10.1007/s10787-017-0390-8. Disponível em: https://link.springer.com/article/10.1007/s10787-017-0390-8. Acesso em: 28 jun. 2023.pt_BR
dc.identifier.doi10.1007/s10787-017-0390-8
dc.identifier.issne- 1568-5608
dc.identifier.issn0925-4692
dc.identifier.urihttps://link.springer.com/article/10.1007/s10787-017-0390-8
dc.language.isoengpt_BR
dc.publisher.countryGra-bretanhapt_BR
dc.publisher.departmentInstituto de Química - IQ (RMG)pt_BR
dc.rightsAcesso Restritopt_BR
dc.subjectAnti-inflammatorypt_BR
dc.subjectN-arylheterocyclespt_BR
dc.subjectIL-1βpt_BR
dc.subjectTNF-αpt_BR
dc.titleAnti-inflammatory effect of a new piperazine derivative: (4-methylpiperazin-1-yl)(1-phenyl-1H-pyrazol-4-yl)methanonept_BR
dc.typeArtigopt_BR

Arquivos

Licença do Pacote
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Baixar

Coleções

IQ - Artigos publicados em periódicos